Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thalamic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Thalamic. Displaying page 1 of 1.
    EudraCT Number: 2018-000684-82 Sponsor Protocol Number: 2017-3968 Start Date*: 2018-03-20
    Sponsor Name:Radboud university medical center
    Full Title: The effect of lactate administration on cerebral blood flow during hypoglycemia
    Medical condition: Type 1 diabetes mellitus (T1DM)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002307-28 Sponsor Protocol Number: GBMTMZ/DOX2015 Start Date*: Information not available in EudraCT
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA MEYER
    Full Title: An open-label, single-center, single-arm Phase II study to evaluate safety and efficacy of doxorubicin in combination with radiotherapy, temozolomide and valproic acid in patients with glioblastoma...
    Medical condition: Glioblastoma multiforme, diffuse intrisic pontine glioma, diffuse glioma of the brain stem and spinal cord, bilateral thalamic glioma, gliomatosis cerebri, anaplastic astrocytoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000283-41 Sponsor Protocol Number: FUMAPMS2016 Start Date*: 2016-09-12
    Sponsor Name:Finn Sellebjerg
    Full Title: Dimethyl fumarate treatment of primary progressive multiple sclerosis
    Medical condition: Primary progressive multiple sclerosis (PPMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001973-21 Sponsor Protocol Number: GNC-402 Start Date*: 2021-07-09
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002648-10 Sponsor Protocol Number: 7109 Start Date*: 2019-04-15
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: TestOsterone TreatmEnt on neuroprotection and Myelin repair in Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000700-29 Sponsor Protocol Number: MD1003CT2016-01MS-SPI2 Start Date*: 2017-02-01
    Sponsor Name:MEDDAY PHARMACEUTICALS SA
    Full Title: Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) HU (Completed) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004822-15 Sponsor Protocol Number: GNC-401 Start Date*: 2020-05-18
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024078-20 Sponsor Protocol Number: RSW2011 Start Date*: 2011-05-11
    Sponsor Name:Instituto Científico y Tecnológico de Navarra
    Full Title: Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pu...
    Medical condition: Malformación capilar cutánea en pacientes con síndrome de Sturge-Weber.
    Disease: Version SOC Term Classification Code Term Level
    13 10042265 Síndrome de Sturge-Weber PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-003577-63 Sponsor Protocol Number: DYNAMICS_Study Start Date*: 2022-04-06
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsing-remitting multiple sclerosis: correlation with disease activity, cognition, fatigue, depression and quality o...
    Medical condition: Multiple sclerosis patients in relapse and remission form
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002568-62 Sponsor Protocol Number: AVB-PGRN-001 Start Date*: 2023-03-13
    Sponsor Name:AviadoBio Ltd
    Full Title: A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal...
    Medical condition: Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-002082-19 Sponsor Protocol Number: LAQ-MS-306 Start Date*: 2013-11-25
    Sponsor Name:Teva Pharmaceutical Industries, Ltd.
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate the Efficacy, Safety and Tolerability of 2 Doses of Oral administration of...
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) SE (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004729-55 Sponsor Protocol Number: GD2CAR02 Start Date*: 2023-07-14
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory central nervous system tumors
    Medical condition: Relapsed/refractory malignant central nervous system tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001313-93 Sponsor Protocol Number: MN39159 Start Date*: 2018-05-03
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
    Medical condition: Progressive multiple sclerosis (PMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) DK (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) HU (Completed) IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002145-11 Sponsor Protocol Number: 101MS329 Start Date*: 2019-03-21
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Rela...
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) NL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 06:15:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA